GSK buys eight years of carbon removal

GSK has agreed to buy more than 500,000 carbon credits from Varaha over eight years, with deliveries of roughly 100,000 tonnes a year arriving between 2028 and 2033, about 7% of the biopharma company's forecast residual emissions on its current carbon reduction pathway. Earthly, a nature-focused investment platform, structured the purchase, and the eight-year term, more than the annual tonnage, is what gives the contract its financing weight.

The credits are generated on farmland in Punjab and Haryana, where Varaha's project funds an expansion of regenerative agriculture across 50,000 hectares, moving participating farmers away from residue burning, intensive tillage and flood-irrigated rice transplanting toward direct seeded rice, reduced tillage and crop residue incorporation. Farmers receive subsidized access to machinery and a share of the revenue the credits produce, and the companies say participating households recorded a 12% to 16% increase in average income during the project's first monitoring period, from higher yields, lower fertilizer costs and that revenue share.

Seven percent is the honest number here. GSK's SBTi-approved target is a 90% absolute cut in emissions across all scopes from a 2020 baseline, net greenhouse gas emissions across its full value chain by 2045, and neutralization of whatever remains, so the credits address a small slice of the residual. Varaha, founded in 2022, has said it wants to sequester one billion tonnes of CO2e on smallholder lands, and deliveries running through 2033 are the kind of contracted revenue a developer can likely take to a lender when it has to fund machinery subsidies, agronomists and soil monitoring years before the first tonne is verified. Adele Cheli, GSK's vice president of environmental sustainability, tied the purchase to business resilience and human health, which reads like a buyer securing a supply relationship rather than clearing one year's obligation.

PWD has argued that transition finance is moving toward named bottlenecks and project-level repricings. This agreement names the bottleneck, changing farm practice across two Indian states with soil carbon as the output, and de-risks it the parallel way, through offtake rather than a repricing clause. GSK carries a purchase obligation; construction exposure and the credits stay with Varaha to verify and deliver. The co-benefit ledger—fine particulate matter, water use, farm income—is what the project must keep producing while it scales, and it is also the part a buyer cannot contract for directly.

The next monitoring period will show whether the 12% to 16% income gain holds as the project scales across all 50,000 hectares; if it does, the smallholder model becomes financeable on evidence rather than on a single corporate buyer's willingness to sign long. First deliveries land in 2028.